Metropolitan Life Insurance Company (MetLife)’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,814	Closed	-$387K	–	2609
2018 Q3	$387K	Hold	21,814	–	–	0.01%	1548
2018 Q2	$301K	Buy	+21,814	New	+$259K	﹤0.01%	1657
2015 Q4	–	Sell	-29,340	Closed	-$134K	–	2667
2015 Q3	$134K	Buy	+29,340	New	+$154K	﹤0.01%	2523
2015 Q2	–	Sell	-33,505	Closed	-$210K	–	2719
2015 Q1	$210K	Buy	33,505 +168	+0.5%	+$970	﹤0.01%	2033
2014 Q4	$210K	Hold	33,337	–	–	﹤0.01%	2385
2014 Q3	$203K	Hold	33,337	–	–	﹤0.01%	2356
2014 Q2	$220K	Buy	33,337 +7,129	+27%	+$80.3K	﹤0.01%	2453
2014 Q1	$624K	Hold	26,208	–	–	﹤0.01%	1653
2013 Q4	$280K	Hold	26,208	–	–	﹤0.01%	2230
2013 Q3	$349K	Hold	26,208	–	–	﹤0.01%	1996
2013 Q2	$344K	Buy	+26,208	New	+$353K	﹤0.01%	1946

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ECYT Position: Q4 2018 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 21,814 shares — an estimated $387K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ECYT in Q2 2013 and held it in 11 quarters. The position peaked at $624K in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Metropolitan Life Insurance Company (MetLife) reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 21,814 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $387K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s Endocyte, Inc. Common Stock position peaked at $624K in Q1 2014.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2018, filed 14 Feb 2019.